TBLR1 and CREBBP as potential novel prognostic immunohistochemical biomarkers in diffuse large B-cell lymphoma. Issue 11 (18th September 2020)

• Record Type: Journal Article
• Authors: Ednersson, Susanne Bram; Stern, Mimmie; Fagman, Henrik; Nilsson-Ehle, Herman; Hasselblom, Sverker; Andersson, Per-Ola
• Is Part Of: Leukemia & lymphoma. Volume 61:Issue 11(2020)
• Page Start: 2595
• Page End: 2604
• Publication Date: 2020-09-18
• Subjects: DLBCL -- CREBBP -- TBLR1 -- prognosis -- digital image analysis; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2020.1775216
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Recent studies have identified prognostic mutational clusters for diffuse large B-cell lymphoma (DLBCL) patients, both within and outside the original cell-of-origin (COO) classification. For many of these mutations, there is limited information regarding the corresponding protein expression. With the aim to determine the relationship of protein expression and intensity to COO and prognosis, we used digital image analysis to quantitate immunohistochemical staining of CREBBP, IRF8, EZH2, and TBLR1 in 209 DLBCL patients. We found that patients with strong nuclear expression of TBLR1 had inferior progression-free survival (PFS) and overall survival (OS) in univariable analysis and inferior PFS in multivariable analysis. Patients with higher proportion of intermediate to strong nuclear CREBBP expression had a worse PFS and OS in univariable analysis. CREBBP was expressed with stronger intensity in non-GCB patients and the prognostic impact was restricted to this subgroup. These findings suggest that high nuclear protein expression of TBLR1 and CREBBP is negatively associated with prognosis in DLBCL.